juststock NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy…
Read More »juststock NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy…
Read More »